BACKGROUND: Docetaxel (Taxotere) has demonstrated high antitumour activity in first- and second-line treatment of metastatic breast cancer. This study analysed the efficacy and toxicity of docetaxel given weekly. PATIENTS AND METHODS: Thirty-five patients with metastatic breast cancer received docetaxel, 35 mg/m2 weekly for six weeks, followed by two weeks without treatment. Additional cycles (three weeks' treatment, two weeks' rest) were given until disease progression. All patients had received prior chemotherapy: 32 and 5 patients had received prior anthracycline-containing and taxane-containing regimens, respectively. Docetaxel was administered for a total of 359 doses (median 9. range 6-22). RESULTS: There was one complete response (3%), 11 partial responses (31%), 17 patients with stable disease (49%) and six with disease progression (17%). Overall response rate was 34% (95% confidential interval (95% CI): 18%-51). Median survival was 307 days; median progression-free survival was 2.6 months (range 1.5 to > or = 5.5 months). Three patients showed grade 3 neutropenia. 14 showed grade 3 alopecia, and various grade 1-2 non-haematological toxicities were observed. Treatment was delayed in two patients due to haematotoxicity. and stopped in one patient due to painful nail toxicity. CONCLUSION: Weekly administration of docetaxel at a dose of 35 mg/m2 is effective and of low toxicity in patients with metastatic breast cancer.
BACKGROUND:Docetaxel (Taxotere) has demonstrated high antitumour activity in first- and second-line treatment of metastatic breast cancer. This study analysed the efficacy and toxicity of docetaxel given weekly. PATIENTS AND METHODS: Thirty-five patients with metastatic breast cancer received docetaxel, 35 mg/m2 weekly for six weeks, followed by two weeks without treatment. Additional cycles (three weeks' treatment, two weeks' rest) were given until disease progression. All patients had received prior chemotherapy: 32 and 5 patients had received prior anthracycline-containing and taxane-containing regimens, respectively. Docetaxel was administered for a total of 359 doses (median 9. range 6-22). RESULTS: There was one complete response (3%), 11 partial responses (31%), 17 patients with stable disease (49%) and six with disease progression (17%). Overall response rate was 34% (95% confidential interval (95% CI): 18%-51). Median survival was 307 days; median progression-free survival was 2.6 months (range 1.5 to > or = 5.5 months). Three patients showed grade 3 neutropenia. 14 showed grade 3 alopecia, and various grade 1-2 non-haematological toxicities were observed. Treatment was delayed in two patients due to haematotoxicity. and stopped in one patient due to painful nail toxicity. CONCLUSION: Weekly administration of docetaxel at a dose of 35 mg/m2 is effective and of low toxicity in patients with metastatic breast cancer.
Authors: Kellie A Slaviero; Stephen J Clarke; Andrew J McLachlan; Elaine Y L Blair; Laurent P Rivory Journal: Br J Clin Pharmacol Date: 2004-01 Impact factor: 4.335
Authors: Martina Baur; Allan T van Oosterom; Véronique Diéras; Michele Tubiana-Hulin; R Charles Coombes; Thomas Hatschek; Michael Murawsky; May Klink-Alakl; Marcus Hudec; Christian Dittrich Journal: J Cancer Res Clin Oncol Date: 2007-07-17 Impact factor: 4.553
Authors: Albert Font; José Miguel Sánchez; Miquel Tarón; Eva Martinez-Balibrea; José Javier Sánchez; José Luis Manzano; Mireia Margelí; Martin Richardet; Agustí Barnadas; Albert Abad; Rafael Rosell Journal: Invest New Drugs Date: 2003-11 Impact factor: 3.850
Authors: T Gamucci; A M D'Ottavio; E Magnolfi; M Barduagni; A Vaccaro; I Sperduti; L Moscetti; F Belli; L Meliffi Journal: Br J Cancer Date: 2007-10-16 Impact factor: 7.640